Agenda

• Relevance of tumor location and tissue biomarkers in treatment decision-making for metastatic colorectal cancer (mCRC)
• Clinical decision-making for patients with mCRC and BRAF V600E mutations; role of BRAF/EGFR inhibition
• Tolerability of BRAF/EGFR-inhibitor combination therapy; spectrum of side effects and optimal management strategies
• Sequencing of regorafenib and TAS-102 for patients with mCRC; use of clinical characteristics to inform this decision
• Available data with and potential clinical role of TAS-102 in combination with bevacizumab for mCRC
• Research findings guiding the FDA approvals of nivolumab, pembrolizumab and nivolumab/ipilimumab for patients with high microsatellite instability/mismatch repair-deficient mCRC; patient selection for anti-PD-1 monotherapy versus combined anti-PD-1/anti-CTLA-4 therapy
• Sequencing of available systemic therapy options for patients with metastatic gastric cancer who have experienced disease progression on first-line therapy; use of biomarkers and clinical factors to select optimal treatment
• Current role of anti-PD-1/PD-L1 antibodies for patients with metastatic gastric or gastroesophageal cancers; rationale for PD-L1 testing
• Frequency and amelioration of side effects associated with immune checkpoint inhibitors for gastric cancer
• Data supporting the FDA approval of TAS-102 for patients with heavily pretreated metastatic gastric cancer; safety and tolerability profile of TAS-102
• Factors guiding the selection of first-line treatment for unresectable hepatocellular carcinoma (HCC); similarities and differences between lenvatinib and sorafenib
• Design, entry criteria and key efficacy and safety findings of the Phase III IMbrave150 trial comparing atezolizumab/bevacizumab to sorafenib as first-line therapy for locally advanced or metastatic HCC
• FDA breakthrough therapy designation and current and future role of atezolizumab/bevacizumab as first-line therapy for locally advanced or metastatic HCC
• Key issues influencing the sequence and selection of approved agents (nivolumab, regorafenib, cabozantinib, pembrolizumab, ramucirumab) for patients with HCC whose disease has progressed on first-line therapy
• Patient education and management of side effects associated with currently available therapeutic agents for HCC

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of gastrointestinal cancers.

Learning Objectives and Goals
Upon completion of this activity, participants should be able to:

• Apply available research data to the therapeutic and supportive care of patients with colorectal cancer (CRC), gastric cancer and hepatocellular carcinoma.
• Recognize the importance of biomarker analysis for patients diagnosed with CRC or gastric or gastroesophageal junction cancer, and use this information to counsel them about evidence-based options for systemic treatment.
• Describe the clinical indications, benefits and toxicities associated with current and recently approved systemic therapies in the management of metastatic CRC.
• Use the results of biomarker assessments (eg, HER2, PD-L1), clinical factors and patient preferences to optimize systemic therapy for locally advanced or metastatic gastric or gastroesophageal junction cancer.
• Communicate the benefits and risks of approved and emerging systemic interventions to patients with locally advanced or metastatic hepatocellular carcinoma.
• Appraise the rationale for and clinical data with commercially available and developmental immune checkpoint inhibitors in the treatment of gastrointestinal cancers.
• Develop a plan to manage the side effects associated with available and recently approved systemic therapies to support quality of life and continuation of treatment.
• Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with gastrointestinal cancers to optimize clinical and quality-of-life outcomes.

Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by RTP.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form, which will be emailed to attendees after the event.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
This activity will be submitted to the ONCC for ILNA verification. The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for CNE (NCPD) credit to utilize this program for ONCC certification or renewal. http://www.ResearchToPractice.com/Meetings/ONS2020/GI/ILNA

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE (NCPD) activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Ms Avella-Howell, Dr Philip and Ms Triglianos have no relevant conflicts of interest to disclose. The following faculty (and his spouse/partner) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr Messersmith — Contracted Research: Aduro Biotech, ALX Oncology, AstraZeneca Pharmaceuticals LP, BeiGene, D3 Pharma, Gossamer Bio, Immunomedics Inc, OncoMed Pharmaceuticals Inc, Pfizer Inc; Data and Safety Monitoring Board/Committee: Five Prime Therapeutics, QED Therapeutics.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

RTP CNE (NCPD) planning committee members, staff and reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from Genentech, a member of the Roche Group, and Taiho Oncology Inc.